12 results on '"ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology."'
Search Results
2. Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma.
3. ImmunoPET Imaging of Renal Cell Carcinoma with (124)I- and (89)Zr-Labeled Anti-CAIX Monoclonal Antibody cG250 in Mice.
4. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.
5. Phase 1 Radioimmunotherapy Study with Lutetium 177-labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
6. Dual contrast agent for computed tomography and magnetic resonance hard tissue imaging.
7. Reply to John Samuel Banerji's Letter to the Editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-Labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma. Eur Urol 2013;63:1101-6.
8. Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
9. Expression and clinical relevance of MET and ALK in Ewing sarcomas.
10. Bone marrow histology in patients with a paroxysmal nocturnal hemoglobinuria clone correlated with clinical parameters.
11. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
12. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.